RKLB vs. BBIO
RKLB (Rocket Lab USA, Inc.) and BBIO (BridgeBio Pharma, Inc.) are both stocks. RKLB operates in Aerospace & Defense (Industrials), while BBIO operates in Biotechnology (Healthcare). Over the past 3 years, RKLB returned 158.32%/yr vs 58.58%/yr for BBIO. At a 0.34 correlation, their price movements are largely independent.
Performance
RKLB vs. BBIO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, RKLB achieves a 46.77% return, which is significantly higher than BBIO's -12.67% return.
RKLB
- 1D
- -10.79%
- 1M
- -17.53%
- YTD
- 46.77%
- 6M
- 66.51%
- 1Y
- 287.84%
- 3Y*
- 158.32%
- 5Y*
- —
- 10Y*
- —
BBIO
- 1D
- -1.11%
- 1M
- -2.64%
- YTD
- -12.67%
- 6M
- -11.11%
- 1Y
- 68.47%
- 3Y*
- 58.58%
- 5Y*
- 0.88%
- 10Y*
- —
RKLB vs. BBIO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
RKLB Rocket Lab USA, Inc. | 46.77% | 173.89% | 360.58% | 46.68% | -69.30% | 8.67% |
BBIO BridgeBio Pharma, Inc. | -12.67% | 178.75% | -32.03% | 429.79% | -54.32% | -66.15% |
Correlation
The correlation between RKLB and BBIO is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.19 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.29 |
Correlation (All Time) Calculated using the full available price history since Aug 24, 2021 | 0.34 |
The correlation between RKLB and BBIO shifts across timeframes, from 0.19 (1 year) to 0.34 (all time), reflecting how their relationship changes across market environments.
Fundamentals
RKLB:
$61.99B
BBIO:
$13.01B
RKLB:
-$0.33
BBIO:
-$3.76
RKLB:
83.69
BBIO:
22.81
RKLB:
$679.58M
BBIO:
$566.04M
RKLB:
$248.43M
BBIO:
$538.20M
RKLB:
-$177.36M
BBIO:
-$602.24M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RKLB vs. BBIO — Risk / Return Rank
RKLB
BBIO
RKLB vs. BBIO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Rocket Lab USA, Inc. (RKLB) and BridgeBio Pharma, Inc. (BBIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RKLB | BBIO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.64 | ||
| Sortino ratioReturn per unit of downside risk | +0.99 | ||
| Omega ratioGain probability vs. loss probability | 1.38 | 1.29 | +0.09 |
| Calmar ratioReturn relative to maximum drawdown | 6.74 | 3.40 | +3.34 |
| Martin ratioReturn relative to average drawdown | 15.44 | 8.27 | +7.17 |
Loading charts...
Drawdowns
RKLB vs. BBIO - Drawdown Comparison
The maximum RKLB drawdown since its inception was -82.96%, smaller than the maximum BBIO drawdown of -92.80%. Use the drawdown chart below to compare losses from any high point for RKLB and BBIO.
Loading charts...
Drawdown Indicators
| RKLB | BBIO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -82.96% | -92.80% | +9.84% |
Max Drawdown (1Y)Largest decline over 1 year | -43.01% | -20.25% | -22.76% |
Max Drawdown (3Y)Largest decline over 3 years | -55.49% | -49.08% | -6.41% |
Max Drawdown (5Y)Largest decline over 5 years | — | -91.89% | — |
Current DrawdownCurrent decline from peak | -31.84% | -16.41% | -15.43% |
Average DrawdownAverage peak-to-trough decline | -51.29% | -45.77% | -5.52% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.75% | 8.31% | +10.44% |
Volatility
RKLB vs. BBIO - Volatility Comparison
Rocket Lab USA, Inc. (RKLB) has a higher volatility of 31.54% compared to BridgeBio Pharma, Inc. (BBIO) at 10.47%. This indicates that RKLB's price experiences larger fluctuations and is considered to be riskier than BBIO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| RKLB | BBIO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 31.54% | 10.47% | +21.07% |
Volatility (6M)Calculated over the trailing 6-month period | 73.47% | 34.18% | +39.29% |
Volatility (1Y)Calculated over the trailing 1-year period | 93.03% | 46.52% | +46.51% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 81.62% | 85.91% | -4.29% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 81.62% | 83.77% | -2.15% |
Dividends
RKLB vs. BBIO - Dividend Comparison
Neither RKLB nor BBIO has paid dividends to shareholders.
Financials
RKLB vs. BBIO - Financials Comparison
This section allows you to compare key financial metrics between Rocket Lab USA, Inc. and BridgeBio Pharma, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
RKLB vs. BBIO - Profitability Comparison
RKLB - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Rocket Lab USA, Inc. reported a gross profit of 76.49M and revenue of 200.35M. Therefore, the gross margin over that period was 38.2%.
BBIO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a gross profit of 178.39M and revenue of 180.60M. Therefore, the gross margin over that period was 98.8%.
RKLB - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Rocket Lab USA, Inc. reported an operating income of -55.97M and revenue of 200.35M, resulting in an operating margin of -27.9%.
BBIO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported an operating income of -105.96M and revenue of 180.60M, resulting in an operating margin of -58.7%.
RKLB - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Rocket Lab USA, Inc. reported a net income of -45.02M and revenue of 200.35M, resulting in a net margin of -22.5%.
BBIO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a net income of -164.04M and revenue of 180.60M, resulting in a net margin of -90.8%.
Frequently Asked Questions
RKLB and BBIO have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
RKLB has higher volatility (31.54%) compared to BBIO (10.47%). In terms of maximum drawdown, RKLB dropped -82.96% vs BBIO's -92.80%.
RKLB currently has the higher Sharpe Ratio (3.12 vs 1.48), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for RKLB and BBIO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer